Levels of circulating mast cell progenitors and tumour‑infiltrating mast cells in patients with colorectal cancer

Zhao, Pingwei; Zhou, Peiwen; Tang, Tongyu; Si, Rui; Ji, Yiding; Hu, Xintong; Li, Ang; Jiang, Yanfang

doi:10.3892/or.2022.8300

Cited by 7 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many researchers have investigated the correlation between MCs and CRC patient prognosis ( Table 1 ). Some authors believe that MCs are correlated with a good prognosis ( 22 , 117 , 118 ), while others believe that mast cells are not associated with prognosis ( 59 , 119 , 120 ), but most studies suggest that mast cells are associated with reduced survival rates ( 2 , 121 – 123 ).…”

Section: Mast Cells and Prognosis In Crcmentioning

confidence: 99%

“…Zhao et al. ( 120 ) reported that circulating mast progenitor cell (MCp) levels are low in CRC patients and are significantly associated with CRC progression, and the frequency of MCps may be an independent indicator of the aggressiveness of CRC in patients and may be used to distinguish between patients with early and advanced CRC. However, mast cells in tumour tissue are not associated with CRC progression.…”

Section: Mast Cells and Prognosis In Crcmentioning

confidence: 99%

See 1 more Smart Citation

Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis

Liu

Huang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The characteristics of the tumour cells, as well as how tumour cells interact with their surroundings, affect the prognosis of cancer patients. The resident cells in the tumour microenvironment are mast cells (MCs), which are known for their functions in allergic responses, but their functions in the cancer milieu have been hotly contested. Several studies have revealed a link between MCs and the development of tumours. Mast cell proliferation in colorectal cancer (CRC) is correlated with angiogenesis, the number of lymph nodes to which the malignancy has spread, and patient prognosis. By releasing angiogenic factors (VEGF-A, CXCL 8, MMP-9, etc.) and lymphangiogenic factors (VEGF-C, VEGF-D, etc.) stored in granules, mast cells play a significant role in the development of CRC. On the other hand, MCs can actively encourage tumour development via pathways including the c-kit/SCF-dependent signaling cascade and histamine production. The impact of MC-derived mediators on tumour growth, the prognostic importance of MCs in patients with various stages of colorectal cancer, and crosstalk between MCs and CRC cells in the tumour microenvironment are discussed in this article. We acknowledge the need for a deeper comprehension of the function of MCs in CRC and the possibility that targeting MCs might be a useful therapeutic approach in the future.

show abstract

Section: Mast Cells and Prognosis In Crcmentioning

confidence: 99%

Section: Mast Cells and Prognosis In Crcmentioning

confidence: 99%

Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis

Liu

Huang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Previous studies have revealed that mast cells had proor anti-tumorigenic roles depending on the tumor types, the stage, and localization within the tumor. Activated mast cells have been shown to be associated with poor prognosis in thyroid cancer (38), gastric cancer (39), hepatic cellular carcinoma (40), and colorectal cancer (41). Mast cell density is increased in gastric cancer, and correlated with angiogenesis, the number of metastatic lymph nodes, and patient survival (42).…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of an immune-related gene signature and infiltrating tumor immune cells based on bioinformatics analysis in primary esophageal cancer

Du¹,

Pang²,

Li³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Immunotherapy is a promising novel treatment for esophageal cancer (ESCA). However, previous studies provide limited direct information about the prognostic significance of immune-related genes (IRGs) in primary ESCA development. This study explored the prognostic value of IRGs and infiltrating tumor immune cells in primary ESCA. Methods: The ribonucleic acid (RNA)-sequencing data and clinical information of primary ESCA were downloaded from The Cancer Genome Atlas (TCGA) database. Which included the clinical factors and prognosis outcomes of the ESCA patients. The IRGs were downloaded from the ImmPORT database. Results: We established the robust IRG prognostic signature of 4 IRGs (i.e., heat shock protein family A member 6, Oncostatin M, androgen receptor, and nuclear receptor subfamily 2 group F member 2) in primary ESCA, and divided the ESCA patients into high-and low-risk groups based on overall survival (OS). The Kaplan-Meier curves showed the high predictive ability of the prognostic signature in the training, testing, and full data sets (P=2.407e-03, P=1.044e-02, and P=2.535e-04, respectively). Multivariate Cox regression analyses were performed with age, grade, tumor stage, tumor type and the risk score as covariables. The risk score supports the use of a prognostic signature as an independent prognostic factor [training data set: hazard ratio (HR) =1.185, 95% confidence interval (95% CI): 1.013-1.388, P=0.034; testing data set: HR =2.056, 95% CI: 1.015-4.166, P=0.045; full data set: HR =1.197, 95% CI: 1.059-1.354, P=0.004]. The area under the curve (AUC) of the receiver operating characteristic curve validated the high predictive accuracy of the IRG signature in the training, testing, and full data set (AUCs =0.808, 0.657, and 0.751, respectively). The infiltration level of the activated mast cells was significantly higher in the high-risk group than the low-risk group; thus, infiltrating mast cells are associated with worse OS in ESCA patients. Conclusions: Our IRG prognostic signature provides a new direction to predict the survival of primaryESCA patients and has the potential ability to establish, promote, and improve personalized treatment procedures based on each patient's risk.

show abstract

“…According to Zhao et al, a lower frequency of circulating MCs and their progenitors was found in patients with CRC than in healthy patients; this was especially apparent in patients with advanced disease. It turned out that this may reflect aggressive CRC course ( 99 ).…”

Section: The Role Of the Immune System In The Prognosis And Treatment...mentioning

confidence: 99%

The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis

Wozniaková

Škarda

Raška³

2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide. The patient’s prognosis largely depends on the tumor stage at diagnosis. The pathological TNM Classification of Malignant Tumors (pTNM) staging of surgically resected cancers represents the main prognostic factor and guidance for decision-making in CRC patients. However, this approach alone is insufficient as a prognostic predictor because clinical outcomes in patients at the same histological tumor stage can still differ. Recently, significant progress in the treatment of CRC has been made due to improvements in both chemotherapy and surgical management. Immunotherapy-based approaches are one of the most rapidly developing areas of tumor therapy. This review summarizes the current knowledge about the tumor microenvironment (TME), immune response and its interactions with CRC development, immunotherapy and prognosis.

show abstract

Levels of circulating mast cell progenitors and tumour‑infiltrating mast cells in patients with colorectal cancer

Cited by 7 publications

References 38 publications

Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis

Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis

The prognostic value of an immune-related gene signature and infiltrating tumor immune cells based on bioinformatics analysis in primary esophageal cancer

The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis

Contact Info

Product

Resources

About